Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]

Latest developments in mHSPC

Prof Kurt Miller and Prof Laura-Maria Krabbe

Latest developments in mHSPC ( Prof Kurt Miller and Prof Laura-Maria Krabbe )

ASCO GU 2022: The latest in CRPC, including PARP combo data

Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel...

ASCO GU 2022: The latest in CRPC, including PARP combo data ( Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Merseburger )

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in...

Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona...

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC ( Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Maintenance PARP inhibition following chemotherapy for metastatic urothelial...

Dr Simon Crabb - University of Southampton, Southampton, UK

Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma ( Dr Simon Crabb - University of Southampton, Southampton, UK )

First randomized trial on adjuvant mitotane in adrenocortical carcinoma...

Prof Alfredo Berruti - University Of Brescia, Brescia, Italy

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study. ( Prof Alfredo Berruti - University Of Brescia, Brescia, Italy )

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible...

Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer ( Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Update on the new EUSOMA quality indicators for breast cancer

Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal

Update on the new EUSOMA quality indicators for breast cancer ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )

The optimal approach after neoadjuvant treatment: The Lucerne toolbox

Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal

The optimal approach after neoadjuvant treatment: The Lucerne toolbox ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )

Tumour agnostic treatments in GI cancer

Dr Nicola Normanno and Dr Katja Schmitz

Tumour agnostic treatments in GI cancer ( Dr Nicola Normanno and Dr Katja Schmitz )

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs...

Prof Peter Schmid - Queen Mary University of London, London, United Kingdom

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC ( Prof Peter Schmid - Queen Mary University of London, London, United Kingdom )

Durvalumab plus chemotherapy significantly improved OS in advanced biliary...

Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South...

Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer ( Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South Korea )

More from ecancer